Molecular epidemiology of carbapenem-resistant gram-negative bacilli in Ecuador

被引:0
|
作者
Soria-Segarra, Claudia [1 ,2 ,3 ,4 ]
Soria-Segarra, Carmen [1 ,5 ]
Molina-Matute, Marcos [6 ]
Agreda-Orellana, Ivanna [6 ]
Nunez-Quezada, Tamara [7 ]
Cevallos-Apolo, Kerly [8 ]
Miranda-Ayala, Marcela [9 ]
Salazar-Tamayo, Grace [10 ]
Galarza-Herrera, Margarita [11 ]
Vega-Hall, Victor [12 ]
Villacis, Jose E. [13 ]
Gutierrez-Fernandez, Jose [3 ,4 ,14 ]
机构
[1] Med Serv, Sosecali, Guayaquil 090308, EC, Ecuador
[2] Guayaquil Univ, Fac Med Sci, Guayaquil, Ecuador
[3] Univ Granada & ibs, Sch Med, Dept Microbiol, Granada, Spain
[4] Univ Granada & ibs, PhD Program Clin Med & Publ Hlth, Granada, Spain
[5] Univ Catolica Santiago Guayaquil, Sch Med, Dept Internal Med, Guayaquil, Ecuador
[6] Hosp Rio, Cuenca, Ecuador
[7] Hosp Inst Ecuatoriano Seguridad Social Dr Teodoro, Guayaquil, Ecuador
[8] Hosp Infectol Dr Jose Daniel Rodriguez Mariduena, Guayaquil, Ecuador
[9] Omni Hosp, Guayaquil, Ecuador
[10] Hosp Vozandez, Quito, Ecuador
[11] Hosp Eugenio Espejo, Quito, Ecuador
[12] Interhosp, Guayaquil, Ecuador
[13] Pontificia Univ Catolica Ecuador, Ctr Invest Salud Amer Latina CISeAL, Quito 17012184, Ecuador
[14] Hosp Virgen Nieves, Inst Biosanit Res Ibs, Dept Microbiol, Granada, Spain
关键词
Carbapenem resistance; Carbapenemase genes; Ecuador; Gram-negative bacilli; COLISTIN RESISTANCE; MULTIPLEX PCR; AMERICA;
D O I
10.1186/s12879-024-09248-6
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction Carbapenem-resistant gram-negative bacilli are a worldwide concern because of high morbidity and mortality rates. Additionally, the increasing prevalence of these bacteria is dangerous. To investigate the extent of antimicrobial resistance and prioritize the utility of novel drugs, we evaluated the molecular characteristics and antimicrobial susceptibility profiles of carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii in Ecuador in 2022.Methods Ninety-five clinical isolates of carbapenem non-susceptible gram-negative bacilli were collected from six hospitals in Ecuador. Carbapenem resistance was confirmed with meropenem disk diffusion assays following Clinical Laboratory Standard Institute guidelines. Carbapenemase production was tested using a modified carbapenemase inactivation method. Antimicrobial susceptibility was tested with a disk diffusion assay, the Vitek 2 System, and gradient diffusion strips. Broth microdilution assays were used to assess colistin susceptibility. All the isolates were screened for the bla KPC, bla NDM, bla OXA-48, bla VIM and bla IMP genes. In addition, A. baumannii isolates were screened for the bla OXA-23, bla OXA-58 and bla OXA-24/40 genes.Results Carbapenemase production was observed in 96.84% of the isolates. The bla KPC, bla NDM and bla OXA-48 genes were detected in Enterobacterales, with bla KPC being predominant. The bla VIM gene was detected in P. aeruginosa, and bla OXA-24/40 predominated in A. baumannii. Most of the isolates showed co-resistance to aminoglycosides, fluoroquinolones, and trimethoprim/sulfamethoxazole. Both ceftazidime/avibactam and meropenem/vaborbactam were active against carbapenem-resistant gram-negative bacilli that produce serin-carbapenemases.Conclusion The epidemiology of carbapenem resistance in Ecuador is dominated by carbapenemase-producing K. pneumoniae harbouring bla KPC. Extensively drug resistant (XDR) P. aeruginosa and A. baumannii were identified, and their identification revealed the urgent need to implement strategies to reduce the dissemination of these strains.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Carbapenem-Resistant Gram-Negative Bacilli Characterization in a Tertiary Care Center from El Bajio, Mexico
    Nieto-Saucedo, Jose Raul
    Lopez-Jacome, Luis Esau
    Franco-Cendejas, Rafael
    Colin-Castro, Claudia Adriana
    Hernandez-Duran, Melissa
    Rivera-Garay, Luis Raul
    Zamarripa-Martinez, Karina Senyase
    Mosqueda-Gomez, Juan Luis
    ANTIBIOTICS-BASEL, 2023, 12 (08):
  • [42] Ceftazidime/avibactam combined with colistin: a novel attempt to treat carbapenem-resistant Gram-negative bacilli infection
    Zheng, Zihao
    Shao, Ziqiang
    Lu, Lihai
    Tang, Siyu
    Shi, Kai
    Gong, Fangxiao
    Liu, Jingquan
    BMC INFECTIOUS DISEASES, 2023, 23 (01)
  • [43] Ceftazidime/avibactam combined with colistin: a novel attempt to treat carbapenem-resistant Gram-negative bacilli infection
    Zihao Zheng
    Ziqiang Shao
    Lihai Lu
    Siyu Tang
    Kai Shi
    Fangxiao Gong
    Jingquan Liu
    BMC Infectious Diseases, 23
  • [44] Routine detection of carbapenem-resistant gram-negative bacilli in clinical laboratories. A review of current challenges
    Al-Zahrani, Ibrahim A.
    SAUDI MEDICAL JOURNAL, 2018, 39 (09) : 861 - 872
  • [45] Faecal carriage of ESBL-producing Enterobacteriaceae and carbapenem-resistant Gram-negative bacilli in community settings
    Edgardo Villar, Hugo
    Noemi Baserni, Marisa
    Beatriz Jugo, Monica
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2013, 7 (08): : 630 - 634
  • [46] Distribution of carbapenem-resistant Gram-negative infections in US hospitals
    McConnell, John
    Mushtaq, Ammara
    LANCET INFECTIOUS DISEASES, 2016, 16 (08): : 898 - 898
  • [48] Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens
    Choby, Jacob E.
    Ozturk, Tugba
    Satola, Sarah W.
    Jacob, Jesse T.
    Weiss, David S.
    LANCET INFECTIOUS DISEASES, 2021, 21 (05): : 597 - 598
  • [49] Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens
    Lee, Chang-Seop
    Doi, Yohei
    INFECTION AND CHEMOTHERAPY, 2014, 46 (03): : 149 - 164
  • [50] Epidemiology, Phenotypic and Genotypic Characterization of Carbapenem-Resistant Gram-Negative Bacteria from a Libyan Hospital
    Slimene, Khouloud
    El Salabi, Allaaeddin
    Dziri, Olfa
    Mathlouthi, Najla
    Diene, Seydina M.
    Mohamed, Elhussan Ahmed
    Amhalhal, Jadalla M. A.
    Aboalgasem, Mohammed O.
    Alrjael, Jomaa F.
    Rolain, Jean-Marc
    Chouchani, Chedly
    MICROBIAL DRUG RESISTANCE, 2023, 29 (08) : 333 - 343